Table 3.
Antimicrobial Resistance Phenotypes and Molecular Characterization of Gene Cassettes in Class 1 Integrons
| Sample no. | Resistance pattern | Int | Length | Gene cassettes | GenBank accession no. |
|---|---|---|---|---|---|
| 1, 2, 4, 8, 9, 15, 17, 20, 22, 26, 27, 29, 30, 31, 34, 38, 38, 44, 45, 47, 49, 50, 52, 53, 55, 56, 57, 60, 62, 63, 64, 65, 66, 67, 68, 69, 73, 74, 75, 76, 77, 78, 79, 80, 82, 84, 89, 93, 95, 96, 98, 102, 106, 107, 109, 110, 112, 114, 115, 116 | Sensitive to all drugs | − | − | − | |
| CS-PA | |||||
| 3, 83 | ATM | − | − | − | |
| 117 | PRL | − | − | − | |
| 25, 51, 92, 94, 99, 105 | CIP, LEV | − | − | − | |
| 85 | ATM, PRL | − | − | − | |
| 13 | LEV, PRL | − | − | − | |
| 41 | ATM, CIP, LEV | − | − | − | |
| 100 | ATM, CIP, LEV | + | − | − | |
| 43 | CAZ, PRL, TZP | − | − | − | |
| 5, 88 | CIP, LEV, IPM | − | − | − | |
| 61 | CIP, LEV, PRL | − | − | − | |
| 104 | CIP, LEV, GEN | + | − | − | |
| 35 | ATM, CSL, PRL | + | 1.1k | AadA22 |
CP041394.1 99.48% |
| 23 | GEN, PRL, TOB, TZP | + | 2.1k | aadB-aac(6′)-1I-pse-1 |
DQ266447.1 97.6 |
| 32 | ATM, CSL, PRL, TZP | − | − | − | |
| 6, 11, 19 | CIP, LEV, IPM, MEM | − | − | ||
| 48 | ATM, CIP, LEV, MEM | − | − | − | |
| 16 | CSL, LEV, IPM, MEM | − | − | − | |
| 87 | ATM, CIP, GEN, LEV, TOB | − | − | − | |
| 108 | ATM, CAZ, CSL, PRL, TOB | − | − | − | |
| 18 | CAZ, CIP, FEP, GEN, LEV, TOB | + | − | − | |
| 111 | AK, ATM, CIP, CSL, GEN, TOB | + | 3.2k | dhfr2-aacA4-aadA1-tna | |
| 97 | ATM, CIP, CSL, GEN, LEV, PRL, TOB | − | − | ||
| 42 | ATM, CAZ, CIP, CSL, GEN, LEV, PRL, TOB, TZP | − | − | − | |
| CR-PA | |||||
| 21 | IPM, MEM, LEV | − | − | − | |
| 14 | IPM, MEM, PRL | − | − | − | |
| 7, 10, 12, 40, 59, 81, 113 | IPM, MEM | − | − | − | |
| 72 | CAZ, IPM, MEM, PRL | − | − | − | |
| 103 | CIP, FEP, LEV, IPM, MEM | − | − | − | |
| 28 | ATM, CAZ, CSL, FEP, IPM, MEM, PRL | − | − | − | |
| 33 | ATM, CAZ, CSL, IPM, MEM, PRL, TZP | − | − | − | |
| 54 | CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | − | − | |
| 71 | AK, ATM, CAZ, CIP, CSL, FEP, IPM, MEN, PRL, TOB, TZP | + | 2.1k | aacA4-blaOXA101-aadA5 | |
| 36, 46, 101 | AK, ATM, CAZ, CIP, CSL, FEP, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.1k | aacA4-blaOXA101-aadA5 | |
| 39, 70 | AK, CAZ, CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.2k+2.8k |
qnrvc-gcu165-arr2-dfrA22e aacA4-gcu35-blaOXA-1-catB3 |
KU984332 KU984333 |
| 24 | AK, ATM, CAZ, CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.1k | aacA4-blaOXA101-aadA5 |
KM111259.1 99.35% |
+, presence of the PCR product; −, absence of the PCR product.
ATM, aztreonam (30 mg); IPM, imipenem (10 mg).